These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 498165)

  • 21. The use of immunohistochemistry in metastatic prostatic adenocarcinoma to the breast.
    Green LK; Klima M
    Hum Pathol; 1991 Mar; 22(3):242-6. PubMed ID: 1706305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemolytic uremic syndrome in metastatic adenocarcinoma of the prostate.
    Mungall S; Mathieson P
    Am J Kidney Dis; 2002 Dec; 40(6):1334-6. PubMed ID: 12460056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone marrow acid phosphatase concentrations in individuals with prostatic carcinoma or other disorders.
    Little C; Shojania AM; Green PT; Weinerman BH
    Can Med Assoc J; 1978 Aug; 119(3):259-61. PubMed ID: 679131
    [No Abstract]   [Full Text] [Related]  

  • 24. Proceedings: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma.
    Yagoda A
    Cancer; 1973 Nov; 32(5):1131-40. PubMed ID: 4271302
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostate specific acid phosphatase: further studies with immunological techniques.
    Davies SN; Griffiths JC
    Clin Chim Acta; 1982 Jun; 122(1):29-38. PubMed ID: 6178538
    [No Abstract]   [Full Text] [Related]  

  • 26. Bone marrow acid phosphatase in staging prostatic carcinoma.
    Pontes JE; Alcorn SW; Thomas AJ; Pierce JM
    J Urol; 1975 Sep; 114(3):422-4. PubMed ID: 1142527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carcinoma of the prostate presenting with massive pleural effusion and elevated pleural acid phosphatase.
    Cassidy MJ; Keeton GR; Berman PA
    Br J Urol; 1985 Oct; 57(5):586-7. PubMed ID: 4063740
    [No Abstract]   [Full Text] [Related]  

  • 28. Purification and characterization of acid phosphatase from Dunning R3327H prostatic adenocarcinoma.
    Lee C; Murphy GP; Chu TM
    Cancer Res; 1980 Apr; 40(4):1245-8. PubMed ID: 7357554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamoxifen in refractory metastatic carcinoma of the prostate.
    Glick JH; Wein A; Padavic K; Negendank W; Harris D; Brodovsky H
    Cancer Treat Rep; 1980; 64(6-7):813-8. PubMed ID: 7427966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case report of a high serum acid phosphatase level in metastatic prostatic adenocarcinoma.
    Sullivan H; Murthy NR
    J Urol; 1971 Sep; 106(3):404. PubMed ID: 5097194
    [No Abstract]   [Full Text] [Related]  

  • 31. Characterization of ALVA-41 cells, a new human prostatic cancer cell line.
    Nakhla AM; Rosner W
    Steroids; 1994 Oct; 59(10):586-9. PubMed ID: 7533340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of serum prostatic acid phosphatase as a tumor marker in men with advanced adenocarcinoma of the prostate.
    Maatman TJ; Gupta MK; Montie JE
    J Urol; 1984 Jul; 132(1):58-60. PubMed ID: 6726962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Relation of serum levels of acid phosphatase in the femoral vein and the inferior vena cava in adenocarcinoma of the prostate].
    De Arruda HO; Srougi M; Wroklawski E; Mello Júnior OM; De Góes GM
    Rev Paul Med; 1981; 97(7-9):113-5. PubMed ID: 7342295
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunohistochemical evaluation of prostatic carcinoma before and after radiotherapy.
    Mahan DE; Bruce AW; Manley PN; Franchi L
    J Urol; 1980 Oct; 124(4):488-91. PubMed ID: 6158585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple myeloma associated with a 9S IgG paraprotein and carcinoma of the prostate.
    Chin CK; Smith LL; Wright CS; Barton BP; Moores RR; Lutcher CL
    Cancer; 1972 Jul; 30(1):206-13. PubMed ID: 4625193
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.
    Smith DC; Jodrell DI; Egorin MJ; Ambinder RM; Zuhowski EG; Kreis W; Ellis PG; Trump DL
    Cancer Chemother Pharmacol; 1993; 31(5):363-8. PubMed ID: 7679331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased acid phosphatase activity in prostate secretion associated with prostatic carcinoma.
    Mourad WA; Straumfjord JV; Persky L; Helal MA; Foulis PR
    Clin Chem; 1990 Aug; 36(8 Pt 1):1517. PubMed ID: 2387049
    [No Abstract]   [Full Text] [Related]  

  • 38. Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report.
    Nishiyama T; Terunuma M
    Int J Urol; 1994 Dec; 1(4):355-6. PubMed ID: 7542158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The chemotherapy of prostatic adenocarcinoma.
    Torti FM; Carter SK
    Ann Intern Med; 1980 May; 92(5):681-9. PubMed ID: 6992675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.
    Graham SD; Walker A; Cox EB; Laszlo J; Berry WR; Paulson DF
    Urology; 1986 Nov; 28(5):404-8. PubMed ID: 3538611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.